Background: Patients with moderate-severe inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis are commonly treated with long-term immunosuppressive therapies involving immunomodulators such as thiopurines, biologics (anti-TNF and anti-adhesion molecules), or novel small molecules such as Janus kinase inhibitors. Summary: Some infections seen with immunosuppressive therapy in IBD are preventable with vaccines. IBD-specific immunosuppressive therapy is generally initiated by gastroenterologists. Therefore, gastroenterologists should comprehend the appropriate application of vaccines such as hepatitis B, pneumonia, and herpes zoster vaccinations. This review summarizes the current guidance for vaccinations of IBD patients in the United States. Key Message: Gastroenterologists treating IBD patients must be aware of necessary vaccination schedules in the setting of immunosuppressive therapies.

Keywords:
Vaccination, Inflammatory bowel diseases, Immunosuppression, Ulcerative colitis, Crohn’s disease
1.
Kim DH, Cheon JH: Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw 2017; 17: 25–40.
2.
Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR: Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. Jama 2011; 306: 2331–2339.
3.
Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA: Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834–1840.
4.
Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929–936.
5.
Selby L, Kane S, Wilson J, Balla P, Riff B, Bingcang C, Hoellein A, Pande S, de Villiers WJ: Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis 2008; 14: 253–258.
6.
Yeung JH, Goodman KJ, Fedorak RN: Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis 2012; 18: 34–40.
7.
Wasan SK, Coukos JA, Farraye FA: Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis 2011; 17: 2536–2540.
8.
Selby L, Hoellein A, Wilson JF: Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Dig Dis Sci 2011; 56: 819–824.
9.
Farraye FA, Melmed GY, Lichtenstein GR, Kane SV: ACG Clinical Guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017; 112: 241–258.
10.
Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF, European Cs, Colitis O: Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443–468.
11.
Centers of Disease Control and Prevention: Measles vaccination. 2016. https://www.cdc.gov/measles/vaccination.html (accessed June 7, 2018).
12.
Centers of Disease Control and Prevention: Measles cases and outbreaks. 2018. https://www.cdc.gov/measles/cases-outbreaks.html (accessed June 7, 2018).
13.
Cleveland NK, Rodriquez D, Wichman A, Pan I, Melmed GY, Rubin DT: Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci 2016; 61: 2972–2976.
14.
Long MD, Gulati A, Wohl D, Herfarth H: Immunizations in pediatric and adult patients with inflammatory bowel disease: a practi cal case-based approach. Inflamm Bowel Dis 2015; 21: 1993–2003.
15.
Gisbert JP, Chaparro M, Esteve M: Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 619–633.
16.
Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bru-ninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E: Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20: 15358–15366.
17.
Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M: Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1460–1466.
18.
Gisbert JP, Menchen L, Garcia-Sanchez V, Marin I, Villagrasa JR, Chaparro M: Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 1379–1385.
19.
Berry SK, Melmed GY: Quality indicators in inflammatory bowel disease. Intest Res 2018; 16: 43–47.
20.
Tinsley A, Williams E, Liu GD, Elwir S, Yoo L, Melmed G, Sands B: The incidence of influenza and influenza-related complications in Inflammatory bowel disease patients across the United States. Am J Gastroenterol 2013; 108:S500–S561.
21.
Kash JC, Taubenberger JK: The role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol 2015; 185: 1528–1536.
22.
Stobaugh DJ, Deepak P, Ehrenpreis ED: Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol 2013; 6: 43–49.
23.
Narula N, Dhillon AS, Chauhan U, Marshall JK: An audit of influenza vaccination status in adults with inflammatory bowel disease. Can J Gastroenterol 2012; 26: 593–596.
24.
Wasan SK, Calderwood AH, Long MD, Kappelman MD, Sandler RS, Farraye FA: Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis 2014; 20: 246–250.
25.
Long MD, Martin C, Sandler RS, Kappelman MD: Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 240–248.
26.
Kantso B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T: Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977–2013. Am J Gastroenterol 2015; 110: 1582–1587.
27.
Ananthakrishnan AN, McGinley EL: Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013; 7: 107–112.
28.
Kim DK, Bridges CB, Harriman KH; Advisory Committee on Immunization Practices (ACIP): Advisory Committee on Immunization Practices Recommended Immunization schedule for adults aged 19 years or older – United States, 2016. Am J Transplant 2016; 16: 1930–1932.
29.
Cullen G, Baden RP, Cheifetz AS: Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2392–2403.
30.
Gupta G, Lautenbach E, Lewis JD: Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483–1490.
31.
Long MD, Martin C, Sandler RS, Kappelman MD: Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 420–429.
32.
Colombel JF: Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis 2018, Epub ahead of print.
33.
Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, Hirose T, Nduaka CI, Wang L, Mendelsohn AM, Fan H, Chen C, Bananis E: Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 2017; 69: 1960–1968.
34.
Khan N, Shah Y, Trivedi C, Lewis JD: Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. Aliment Pharmacol Ther 2017; 46: 668–672.
35.
Centers of Disease Control and Prevention: Recommended immunization schedule for adults aged 19 years or older, United States, 2018. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html#f4 (accessed June 7, 2018).
36.
Dooling KL, Guo A, Patel M, Lee GM, Moore K, B elongia EA, Harpaz R: Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67: 103–108.
37.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I: 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44–e100.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.